General
Preferred name
COBIMETINIB
Synonyms
RG-7420, GDC-0973, Cobimetinib Fumarate, XL-518, RG-7420, RG-7421, GDC-0973 ()
RG7420 ()
XL518 ()
GDC-0973 ()
Cobimetinib hemifumarate ()
CobimetinibGDC-0973GDC0973A-1180 ()
COTELLIC ()
GDC 0623 ()
GDC 0973 ()
GDC-0623 ()
RG 7420 ()
RG-7420 ()
RG-7421 ()
XL 518 ()
XL-518 ()
Cobimetinib (GDC-0973) ()
RG7420,XL518 ()
Gdc-0623 ()
XL-518 hemifumarate ()
GDC-0973 hemifumarate ()
COBIMETINIB FUMARATE ()
P&D ID
PD009336
CAS
934660-93-2
1369665-02-0
Tags
available
drug
Approved by
EMA
FDA
First approval
2015
Drug Status
approved
investigational
Max Phase
4.0
Drug indication
Metastatic melanoma
Neoplasm
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Cobimetinib is an allosteric inhibitor of MEK serine/threonine protein kinases, with selectivity for MEK1 and MEK2 .
Note that cobimetinib has been erroneously referred to as cometinib and this has propagated in online resources- cometinib is not an official synonym. (GtoPdb)
Note that cobimetinib has been erroneously referred to as cometinib and this has propagated in online resources- cometinib is not an official synonym. (GtoPdb)
DESCRIPTION
Cobimetinib is an allosteric inhibitor of MEK serine/threonine protein kinases, with selectivity for MEK1 and MEK2 .
DESCRIPTION
Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral MEK1 inhibitor with an IC50 of 4.2 nM for MEK1.
PRICE
100
DESCRIPTION
For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.
(PKIDB)
DESCRIPTION
Cobimetinib (GDC-0973) is a MEK1 inhibitor (IC50=4.2 nM) with selective and oral activity. Cobimetinib exhibits antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Cobimetinib, also known as GDC-0973 and XL-518, is a novel selective MEK inhibitor, and the IC50value against MEK1 is 4.2 nM, with potential antineoplastic activity.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
0
Compound Sets
27
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
EUbOPEN Chemogenomics Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
167
Molecular Weight
531.06
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
2
cLogP
3.78
TPSA
64.6
Fraction CSP3
0.38
Chiral centers
1.0
Largest ring
6.0
QED
0.53
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Targets
MAP2K1
Target
Apoptosis
MEK
MEK1
Apoptosis related,MEK
Indication
melanoma
MOA
MEK inhibitor
Pathway
MAPK/ERK Pathway
MAPK
Solubility
DMSO
Recommended Cell Concentration
1 uM
Source data

